SEC Form 4 · accession 0001104659-17-012179
SUPERNUS PHARMACEUTICALS, INC. · SUPN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Stefan K.F. Schwabe
Officer — Executive Vice President R&D
Period of report
Feb 24, 2017
Accepted (ET)
Feb 27, 2017 · 9:59 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001356576
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | holding | — | — | — | 1,531 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F2 | $25.30 | Feb 24, 2017 | A | 50,000 | A | — | Feb 24, 2027 | Common Stock | 50,000 | 50,000 | D |
Explanation of responses
- F1Includes an aggregate of 794 shares acquired by the Reporting Person through the Issuer's Employee Stock Purchase Plan subsequent to the date of the Reporting Person's most recent filing on Form 4.
- F2The option vests in four equal installments beginning on February 24, 2018.